Unscheduled Cancer Pain Admissions Costly: Close to $5 Million a Year at M.D. Anderson

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

HOUSTON-Unscheduled hospital admissions for treatment of pain represent a significant cost-$4.7 million annually in a study from The University of Texas M.D. Anderson Cancer Center.

HOUSTON-Unscheduled hospital admissions for treatment of painrepresent a significant cost-$4.7 million annually in a studyfrom The University of Texas M.D. Anderson Cancer Center.

Monica M. Larsen, BA, of the Department of Pharmacoeconomics,who presented the abstract at the 8th World Congress on Pain,said that more effective outpatient pain interventions are thekey to reducing these expensive admissions.

Ms. Larsen and her colleagues reviewed the records of all patientsadmitted through the emergency care unit over a 6-month period.

Of the 1,166 total admissions, 14% were for pain, ranking secondonly to fever (35%). The reasons for the pain admissions werepain management (60%), abdominal pain (24%), chest pain (10%),headache (5%), and back pain (1%).

The mean length of stay for pain admissions was 10.5 days, andthe mean patient charge per admission was $19,000 ($1,800 perday).

Using the hospital-specific cost-to-charge ratio of 0.74, theresearchers determined that the actual hospital cost per admissionfor pain was $14,000 ($1,300 per day). Thus, they were able topredict an annual cost of about $4.7 million for unscheduled painadmissions.

Recent Videos
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.